Document is current
Any future updates will be listed below
-
Authors
Lobel, Joseph H.
Ingolia, Nicholas T.
-
Funding
Funding for this research was provided by:
National Institute of General Medical Sciences (F32 GM148044, R01 GM135233)
National Human Genome Research Institute (R21 HG012991)
- License Information
-
More Information
Article History
Received: 31 July 2024
Accepted: 7 May 2025
First Online: 25 May 2025
Declarations
:
: Not applicable.
: Not applicable.
: N.T.I. holds equity and serves as a scientific advisor to Tevard Biosciences, and holds equity in Velia Therapeutics. J.H.L. declares no competing interests.
